TransMedics Group, Inc. Aktie News

ANDOVER, Mass., 10. Sept. 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), der weltweit führende Anbieter tragbarer Warmperfusion für Spenderorgane zur Transplantation, gab heute die Ernennung von Fernando Araujo zum Chief Financial Officer mit Wirkung zum 21. September 2026 bekannt.

ANDOVER, Mass., 4. Aug. 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), ein Medizintechnologieunternehmen, das die Organtransplantationstherapie für Patienten mit terminalem Lungen-, Herz- und Leberversagen transformiert, gab heute die Finanzergebnisse für das zum 30. Juni 2026 endende Quartal bekannt.

ANDOVER, Mass., Aug. 3, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 29, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762 shares of its common stock and an aggre...

Die strategische Investition in das in Deutschland ansässige PAD Aviation, einen führenden europäischen Betreiber privater Luftfahrt, schafft die Grundlage für TransMedics, ein dediziertes Luftlogistiknetzwerk für Organtransplantationen in ganz Europa aufzubauen ANDOVER, Mass., 6. Juli 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), ein Medizintechnikunternehmen, da...

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (NASDAQ: TMDX) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.

ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 19, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 37,367 shares of its common stock and an aggreg...

ANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026.